Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
Immune checkpoint inhibitors targeting PD-1 and PD-L1 have demonstrated anti-tumor activity in several advanced solid malignancies. In previously treated metastatic castration resistant prostate cancer (mCRPC), a small subset of patients have a therapeutic response to checkpoint inhibition. Those wh...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-08-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920936084 |
id |
doaj-80871f0d1b744f7e94aedb7cb2b6adbb |
---|---|
record_format |
Article |
spelling |
doaj-80871f0d1b744f7e94aedb7cb2b6adbb2020-11-25T03:11:30ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592020-08-011210.1177/1758835920936084Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancerHarry J. HanYun Rose LiMack RoachRahul AggarwalImmune checkpoint inhibitors targeting PD-1 and PD-L1 have demonstrated anti-tumor activity in several advanced solid malignancies. In previously treated metastatic castration resistant prostate cancer (mCRPC), a small subset of patients have a therapeutic response to checkpoint inhibition. Those who do respond to anti-PD-1/PD-L1 therapy have a marked, durable response to treatment, suggesting some derive long-term benefit from immune checkpoint blockade. In other cancers, one strategy to increase the efficacy of immune checkpoint blockade is to combine it with a pro-immune stimulatory agent, such as radiation. Here we present a case of a patient with heavily treated mCRPC who had a significant tumor response to concurrent pembrolizumab and radiation therapy to the primary prostatic mass. We review the growing evidence supporting the use of this combination therapy in other cancers and its potential benefit and safety in mCRPC. Our report highlights a potential therapeutic approach that should be further investigated in previously treated mCRPC.https://doi.org/10.1177/1758835920936084 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Harry J. Han Yun Rose Li Mack Roach Rahul Aggarwal |
spellingShingle |
Harry J. Han Yun Rose Li Mack Roach Rahul Aggarwal Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer Therapeutic Advances in Medical Oncology |
author_facet |
Harry J. Han Yun Rose Li Mack Roach Rahul Aggarwal |
author_sort |
Harry J. Han |
title |
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer |
title_short |
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer |
title_full |
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer |
title_fullStr |
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer |
title_full_unstemmed |
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer |
title_sort |
dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Medical Oncology |
issn |
1758-8359 |
publishDate |
2020-08-01 |
description |
Immune checkpoint inhibitors targeting PD-1 and PD-L1 have demonstrated anti-tumor activity in several advanced solid malignancies. In previously treated metastatic castration resistant prostate cancer (mCRPC), a small subset of patients have a therapeutic response to checkpoint inhibition. Those who do respond to anti-PD-1/PD-L1 therapy have a marked, durable response to treatment, suggesting some derive long-term benefit from immune checkpoint blockade. In other cancers, one strategy to increase the efficacy of immune checkpoint blockade is to combine it with a pro-immune stimulatory agent, such as radiation. Here we present a case of a patient with heavily treated mCRPC who had a significant tumor response to concurrent pembrolizumab and radiation therapy to the primary prostatic mass. We review the growing evidence supporting the use of this combination therapy in other cancers and its potential benefit and safety in mCRPC. Our report highlights a potential therapeutic approach that should be further investigated in previously treated mCRPC. |
url |
https://doi.org/10.1177/1758835920936084 |
work_keys_str_mv |
AT harryjhan dramaticresponsetocombinationpembrolizumabandradiationinmetastaticcastrationresistantprostatecancer AT yunroseli dramaticresponsetocombinationpembrolizumabandradiationinmetastaticcastrationresistantprostatecancer AT mackroach dramaticresponsetocombinationpembrolizumabandradiationinmetastaticcastrationresistantprostatecancer AT rahulaggarwal dramaticresponsetocombinationpembrolizumabandradiationinmetastaticcastrationresistantprostatecancer |
_version_ |
1724653752610193408 |